Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 05/22/2026

BPTSY vs. ORGS, SBFM, CANF, QLGN, and TRIB

Should you buy Biophytis stock or one of its competitors? MarketBeat compares Biophytis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biophytis include Orgenesis (ORGS), Sunshine Biopharma (SBFM), Can-Fite BioPharma (CANF), Qualigen Therapeutics (QLGN), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry.

How does Biophytis compare to Orgenesis?

Biophytis (NASDAQ:BPTSY) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market.

Biophytis has higher earnings, but lower revenue than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Orgenesis	$662K	4.61	-$55.36M	-$11.51	N/A

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Orgenesis	Neutral

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Sunshine Biopharma currently has a consensus price target of $7.00, suggesting a potential upside of 1,354.39%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Sunshine Biopharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Sunshine Biopharma's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
Biophytis	Neutral

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.0% of Sunshine Biopharma shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sunshine Biopharma has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.07	-$5.97M	-$1.29	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Biophytis has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Biophytis' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Biophytis	N/A	N/A	N/A

Summary

Sunshine Biopharma beats Biophytis on 6 of the 11 factors compared between the two stocks.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Can-Fite BioPharma's average media sentiment score of 0.34 beat Biophytis' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Biophytis	Neutral

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.50	-$7.63M	-$35.80	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Can-Fite BioPharma currently has a consensus target price of $42.50, suggesting a potential upside of 1,150.00%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Can-Fite BioPharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Can-Fite BioPharma beats Biophytis on 7 of the 9 factors compared between the two stocks.

How does Biophytis compare to Qualigen Therapeutics?

Biophytis (NASDAQ:BPTSY) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Qualigen Therapeutics	Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Summary

Biophytis and Qualigen Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Biophytis compare to Trinity Biotech?

Biophytis (NASDAQ:BPTSY) and Trinity Biotech (NASDAQ:TRIB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Biophytis has higher earnings, but lower revenue than Trinity Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Trinity Biotech	$43.78M	0.05	-$37.38M	-$3.90	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Trinity Biotech had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Biophytis. Biophytis' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Trinity Biotech	Neutral

0.1% of Biophytis shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biophytis has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Trinity Biotech	-85.36%	N/A	-36.62%

Summary

Trinity Biotech beats Biophytis on 5 of the 8 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$586K	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	N/A	1.46	21.22	25.66
Price / Sales	N/A	119.63	562.28	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	-0.02	7.59	10.31	7.14
Net Income	-$18.43M	-$3.64M	$3.57B	$335.98M
7 Day Performance	N/A	3.01%	6.43%	4.15%
1 Month Performance	N/A	76.62%	3.57%	2.54%
1 Year Performance	-85.55%	126.61%	34.07%	35.06%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
ORGS Orgenesis	N/A	$0.45 +863.6%	N/A	-68.9%	$2.33M	$662K	N/A	150	Gap Up
SBFM Sunshine Biopharma	2.5373 of 5 stars	$0.44 -13.7%	$7.00 +1,490.9%	-66.6%	$2.20M	$36.31M	N/A	3	Gap Down High Trading Volume
CANF Can-Fite BioPharma	2.4029 of 5 stars	$3.25 -0.3%	$42.50 +1,207.7%	-83.6%	$2.13M	$405K	N/A	8
QLGN Qualigen Therapeutics	N/A	$1.23 -3.9%	N/A	-65.8%	$2.09M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. ORGS, SBFM, CANF, QLGN, and TRIB

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to Sunshine Biopharma?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Summary

How does Biophytis compare to Qualigen Therapeutics?

Summary

How does Biophytis compare to Trinity Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. ORGS, SBFM, CANF, QLGN, and TRIB

How does Biophytis compare to Orgenesis?

Is BPTSY or ORGS more profitable?

Do institutionals and insiders hold more shares of BPTSY or ORGS?

Which has more risk and volatility, BPTSY or ORGS?

Which has stronger earnings and valuation, BPTSY or ORGS?

Does the media prefer BPTSY or ORGS?

Summary

How does Biophytis compare to Sunshine Biopharma?

Do analysts prefer SBFM or BPTSY?

Does the media prefer SBFM or BPTSY?

Do institutionals & insiders have more ownership in SBFM or BPTSY?

Which has more risk and volatility, SBFM or BPTSY?

Which has higher earnings & valuation, SBFM or BPTSY?

Is SBFM or BPTSY more profitable?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Does the media refer more to CANF or BPTSY?

Which has better earnings and valuation, CANF or BPTSY?

Do analysts prefer CANF or BPTSY?

Which has more volatility and risk, CANF or BPTSY?

Is CANF or BPTSY more profitable?

Do institutionals and insiders hold more shares of CANF or BPTSY?

Summary

How does Biophytis compare to Qualigen Therapeutics?

Which has more risk & volatility, BPTSY or QLGN?

Does the media favor BPTSY or QLGN?

Do insiders and institutionals hold more shares of BPTSY or QLGN?

Is BPTSY or QLGN more profitable?

Do analysts prefer BPTSY or QLGN?

Which has stronger earnings & valuation, BPTSY or QLGN?

Summary

How does Biophytis compare to Trinity Biotech?

Which has higher valuation and earnings, BPTSY or TRIB?

Do analysts recommend BPTSY or TRIB?

Does the media favor BPTSY or TRIB?

Do institutionals & insiders believe in BPTSY or TRIB?

Is BPTSY or TRIB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools